HS-005

Asset

Transplanted allogeneic iPSC-derived cardiomyocyte spheroids regenerate heart muscle to improve cardiac function.

Stage
Phase 1
Modality
Cell therapy
Target
Not known
4
Indications
1
Trial
1
Developer

Trial NCT07347197 is still running. Trial NCT07347197 updated in its registry on Oct 22, 2026. clinicaltrials.gov

Indications

4

1 more

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors8
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets